A sustained-release formula and a medicine pillow for preventing and treating allergic rhinitis

Abstract

This application discloses a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis, including a pillow base with two symmetrically arranged sustained-release mechanisms and a drive mechanism in the bottom mounting compartment. The sustained-release mechanism consists of multiple sustained-release components, each containing a sustained-release tube and a drug storage tube, connected by a U-shaped connecting pipe and a one-way valve; the drug storage tube is inserted into a pierced tube with a filter screen, which balances air pressure and prevents contamination. The drive mechanism drives a sliding valve to reciprocate via a worm gear system, achieving quantitative drug extraction and precise sustained-release; the atomization design of the sustained-release port improves drug absorption efficiency, and the guide holes in the mounting compartment and the ventilation grooves on the pillow surface form a uniform diffusion channel. This solution solves the problems of cumbersome drug replacement, uncontrollable volatilization, and easy deterioration associated with traditional medicated pillows, offering advantages such as precise controlled release, convenient maintenance, and multiple safety protections. It allows for individualized drug administration based on drug characteristics and patient rhythms, significantly improving the effectiveness of sleep aid therapy and the user experience.

Description

Technical Field

[0001] This application belongs to the field of medical physiotherapy, and specifically relates to a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis. Background Technology

[0002] Sleep is a basic physiological need for humans to maintain life and health. However, according to the "2025 China Sleep Quality Survey Report," approximately 38.2% of adults in my country suffer from sleep disorders. Among these, allergic rhinitis is a significant contributing factor to sleep apnea and frequent awakenings at night. The global prevalence of allergic rhinitis has reached 10%–25%. Patients often experience sleep structure disorders due to symptoms such as nasal congestion, itching, and sneezing. Daytime sleepiness and poor concentration severely impact their quality of life and work efficiency.

[0003] Current clinical treatment options for allergic rhinitis have many limitations:

[0004] Poor adherence to medication: Oral antihistamines are prone to causing systemic side effects such as drowsiness and dry mouth, and long-term use may also lead to drug resistance; Nasal corticosteroid sprays require regular daily administration, and more than 60% of patients stop taking the medication on their own due to the cumbersome operation and concerns about local irritation, resulting in recurring symptoms.

[0005] Physical therapy has limited effectiveness: nasal irrigation, acupuncture and other adjunctive therapies can only temporarily relieve symptoms and cannot achieve long-term stable disease control. Furthermore, the efficacy varies significantly depending on the standardization of the procedure.

[0006] Surgical treatment carries a high risk: invasive treatments such as pterygopalatine ganglion resection carry the risk of irreversible complications such as dry eye and nasal dryness, and are only suitable for a very small number of refractory cases.

[0007] Traditional Chinese medicine olfactory therapy (medicated pillow therapy), a classic external treatment method in TCM, involves the continuous inhalation of volatile drug molecules during sleep. These molecules are absorbed through the nasal mucosa and act directly on the affected area, offering advantages such as minimal systemic side effects and high patient acceptance. Traditional medicated pillows typically use pulverized Chinese medicinal herbs as filling, but this method has several insurmountable drawbacks in practical application:

[0008] 1. Inefficient medication management: Traditional herbal pillows require regular disassembly of the pillowcase and replacement of the medication filling layer, an operation that takes about 20-30 minutes and cannot achieve precise switching between medications with different effects; some herbal pillows use a sealed packaging design, and replacing medications requires damaging the overall structure, resulting in a shortened product lifespan.

[0009] 2. Difficulty in ensuring drug stability: Chinese medicinal materials are directly exposed to the air and are easily affected by temperature and humidity, resulting in oxidation, deliquescence, mold and other deterioration reactions. Studies have shown that the loss rate of effective ingredients in medicinal pillows during the plum rain season in southern China can reach more than 40%. At the same time, the sweat and breath moisture produced by the human body during sleep will accelerate the degradation of the drugs, causing hygiene problems such as odor and microbial growth.

[0010] 3. The release process cannot be precisely controlled: the drug evaporation rate is entirely dependent on environmental conditions. When the temperature drops at night, the evaporation rate decreases by 30%-50%, which cannot match the physiological rhythm of the human sleep cycle. Moreover, the diffusion range of drug molecules is limited to the occipital region, and the effective concentration can only cover the anterior 1 / 3 of the nasal cavity, affecting the treatment effect.

[0011] 4. Inadequate safety protection system: Traditional fabric pillowcases have a flame retardant rating of only B1, which cannot meet the fire safety requirements of the bedroom; the open filling structure poses a risk of children accidentally ingesting drug particles, and direct contact of drugs with the skin may cause allergic reactions such as contact dermatitis.

[0012] In recent years, some researchers have attempted to apply sustained-release technology to the field of medicated pillows, such as using microencapsulation technology to prepare sustained-release drug cores. However, problems such as low encapsulation efficiency and uneven release rates still exist. Others have designed medicated pillows with heating devices to regulate evaporation through temperature control, but these consume a lot of energy and pose a risk of burns. These improvements have not fundamentally solved the core defects of traditional medicated pillows. Therefore, there is an urgent need to develop a modern drug-releasing sleep device that combines precise controlled release, convenient maintenance, and safety. This application proposes a systematic solution to the above-mentioned defects, filling the gap in existing medicated pillow technology. Summary of the Invention

[0013] To achieve the above objectives, this application provides a sustained-release formula for preventing and treating allergic rhinitis. One dose includes 400g-500g of chrysanthemum, 27g-33g of roasted Xanthium sibiricum, 52g-66g of Saposhnikovia divaricata, 52g-66g of Centipeda minima, 17g-22g of rose, 53g-66g of wild chrysanthemum, 24g-33g of Magnolia biondii, 53g-66g of Angelica dahurica, 16g-22g of peppermint, 57g-68g of Albizia julibrissin, 54g-62g of honeysuckle, 26g-33g of Notopterygium incisum, 18g-25g of Asarum heterotropoides, and 27g-35g of Ligusticum striatum. The herbs are mixed in proportion and then pulverized at low temperature. The particle size of the pulverized material is controlled to be 100-200 mesh. After mixing and homogenization, the moisture content of the material is controlled to be below 3%. After low-temperature pulverization and homogenization, the mixture is filled into a pillow.

[0014] A sustained-release medicated pillow for preventing and treating allergic rhinitis includes a pillow base, an installation chamber at the bottom of the pillow base, two sets of sustained-release mechanisms symmetrically installed in the installation chamber along a central axis, and a drive mechanism installed between the two sets of sustained-release mechanisms through the installation chamber, the drive mechanism being used to drive the two sets of sustained-release mechanisms.

[0015] The sustained-release mechanism consists of multiple sets of sustained-release components arranged in parallel. Each sustained-release component includes a sustained-release tube and a drug storage tube, which are connected by a U-shaped connecting pipe. A first one-way valve is installed inside the U-shaped connecting pipe. The drug storage tube is inserted into a piercing tube, which is placed in a placement groove. The placement groove is fixedly installed in the installation chamber. A sliding valve is slidably installed inside the sustained-release tube. The sliding valve extends out of the sustained-release tube through a guide groove and is connected to the drive mechanism. The guide groove is opened through the sustained-release tube on the side near the end of the installation chamber. A sustained-release port is provided on the side of the sustained-release tube near the drive mechanism.

[0016] In one embodiment, a second one-way valve is provided in the sustained-release port. The first one-way valve flows from the drug storage tube to the sustained-release tube, and the second one-way valve flows from the sustained-release tube to the installation compartment.

[0017] In one embodiment, a tail plug is provided at the junction of the drug storage tube and the piercing tube, and a head plug is provided at the junction of the drug storage tube and the U-shaped connecting tube.

[0018] In one embodiment, both the tail plug and the head plug are made of rubber and are sealed at the connection with the drug storage tube.

[0019] In one embodiment, the piercing tube extends through the mounting chamber and connects to the outside, and a filter screen is also provided on the piercing tube.

[0020] In one embodiment, the inner wall of the installation chamber is provided with multiple guide holes, and the pillow seat is provided with a pillow surface.

[0021] In one embodiment, the drive mechanism includes a pull rod connected to the sliding valve, a first connecting rod between the pull rods, a second connecting rod rotatably connected to the first connecting rod via a rotating shaft, the end of the second connecting rod away from the first connecting rod being rotatably mounted on a worm gear via a rotating shaft, the worm gear being rotatably mounted inside the mounting chamber, the worm gear meshing with a worm, the input end of the worm being connected to the output end of a motor, and the motor being mounted inside the mounting chamber.

[0022] Compared with the prior art, the beneficial effects of this application are:

[0023] 1. A controllable drug release system, featuring the technical characteristics of worm gear drive + reciprocating motion of sliding valve.

[0024] The worm gear transmission system of the drive mechanism works in conjunction with the reciprocating motion of the sliding valve to achieve quantitative extraction and timed release of drugs. The displacement of the sliding valve can be precisely controlled by adjusting the motor speed, ensuring drug release accuracy and solving the problem of uncontrollable evaporation rates in traditional medicated pillows. It also supports multiple preset sustained-release modes, enabling individualized drug administration based on the different physicochemical properties of the drugs and the patient's sleep cycle rhythm. For example, high-frequency drug release in the first half of the night promotes sleep, while automatic frequency reduction in the second half of the night reduces residual effects the next day, significantly improving treatment accuracy and suitability.

[0025] 2. A convenient and efficient drug maintenance solution, featuring a plug-in drug reservoir tube and double-sealed plugs.

[0026] Featuring a pluggable medication reservoir design, medication replacement requires no disassembly of the pillow body; simply pull out the reservoir, inject the medication, and then plug it back in—a simple and quick process. The rubber caps at both ends of the reservoir provide a double seal, and combined with the one-way ventilation function of the puncture tube, significantly extend the medication's shelf life and effectively prevent moisture absorption and oxidation. Furthermore, the independently sealed reservoir design allows for quick switching between different medication formulations based on the patient's condition, greatly improving flexibility and maintenance efficiency.

[0027] 3. A multi-layered safety protection system, featuring dual one-way valve circuits and a piercing tube filter.

[0028] The first and second one-way valves work together to form a bidirectional pressure regulation loop, preventing drug backflow and cross-contamination. The high-efficiency filter at the puncture tube effectively blocks environmental dust and microorganisms, preventing external pollutants from entering the drug storage system. The pillow body is made of high-grade flame-retardant materials, combined with a sealed installation compartment structure, which not only meets the fire safety requirements of bedrooms but also effectively prevents children from accidentally taking the medicine, solving the problem of insufficient safety of traditional medicine pillows.

[0029] 4. Optimized drug utilization efficiency, corresponding to the technical features of the nebulizer sustained-release port + guide hole ventilation channel.

[0030] The atomizing nozzle design at the sustained-release port atomizes the drug solution into fine particles, significantly improving transdermal absorption efficiency. The guide holes on the inner wall of the mounting chamber and the ventilation grooves on the pillow surface form a through-flow airflow channel, allowing drug molecules to diffuse evenly into the area surrounding the nasal cavity, expanding the effective range and solving the problem of limited drug diffusion in traditional medicated pillows. Simultaneously, the pressure-balanced design of the puncture tube ensures smooth drug flow from the reservoir, avoiding drug waste caused by negative pressure blockage. Attached Figure Description

[0031] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0032] Figure 1 A schematic diagram of the bottom of a sustained-release medicated pillow for preventing and treating allergic rhinitis provided in this application;

[0033] Figure 2 A schematic diagram of the internal connections of a sustained-release medicated pillow for preventing and treating allergic rhinitis provided in this application;

[0034] Figure 3 A schematic diagram of the internal bottom connection of a sustained-release medicated pillow for preventing and treating allergic rhinitis provided in this application;

[0035] Figure 4 Provided for this application Figure 1 Enlarged view of point A in the middle;

[0036] Figure 5 Provided for this application Figure 1 Enlarged view of point B in the middle;

[0037] Figure 6 A front view of a sustained-release medicated pillow for preventing and treating allergic rhinitis, provided in this application.

[0038] Explanation of reference numerals in the attached drawings: 1. Pillow seat; 2. Installation compartment; 3. Slow-release mechanism; 31. Slow-release tube; 32. Drug storage tube; 33. Tail plug; 34. First plug; 36. Slow-release port; 37. Guide groove; 38. Placement groove; 39. Piercing tube; 5. Guide hole; 6. Drive mechanism; 61. U-shaped connecting pipe; 62. Pull rod; 63. First connecting rod; 64. First one-way valve; 65. Second connecting rod; 66. Worm gear; 67. Worm; 68. Motor; 7. Filter screen; 8. Pillow surface. Detailed Implementation

[0039] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions in the embodiments of this application are described clearly and completely below. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. Based on the embodiments in this application, all other embodiments obtained by those skilled in the art without creative effort are also within the scope of protection of this application.

[0040] See Figures 1 to 6As shown, this application provides a sustained-release formula for preventing and treating allergic rhinitis. One dose includes 400g-500g of chrysanthemum, 27g-33g of roasted Xanthium sibiricum, 52g-66g of Saposhnikovia divaricata, 52g-66g of Centipeda minima, 17g-22g of rose, 53g-66g of wild chrysanthemum, 24g-33g of Magnolia biondii, 53g-66g of Angelica dahurica, 16g-22g of peppermint, 57g-68g of Albizia julibrissin, 54g-62g of honeysuckle, 26g-33g of Notopterygium incisum, 18g-25g of Asarum heterotropoides, and 27g-35g of Ligusticum striatum. The herbs are mixed in proportion and then pulverized at low temperature. The particle size of the pulverized material is controlled to be 100-200 mesh. After mixing and homogenization, the moisture content of the material is controlled to be below 3%. After low-temperature pulverization and homogenization, the mixture is filled into a pillow.

[0041] A sustained-release medicated pillow for preventing and treating allergic rhinitis includes a pillow base 1. An installation chamber 2 is opened at the bottom of the pillow base 1. Two sets of sustained-release mechanisms 3 are symmetrically installed in the installation chamber 2 along the central axis. A drive mechanism 6 is installed between the two sets of sustained-release mechanisms 3 through the installation chamber 2. The drive mechanism 6 is used to drive the two sets of sustained-release mechanisms 3.

[0042] According to the patient's treatment needs, the drug is placed in the sustained-release mechanism 3, and the driving mechanism 6 is activated to drive and regulate the sustained-release mechanism 3, so that the therapeutic drug is released on demand, achieving controlled and timed release.

[0043] The sustained-release mechanism 3 consists of multiple sets of sustained-release components arranged in parallel. Each sustained-release component includes a sustained-release tube 31 and a drug storage tube 32. The sustained-release tube 31 and the drug storage tube 32 are connected by a U-shaped connecting pipe 61. A first one-way valve 64 is provided inside the U-shaped connecting pipe 61. The drug storage tube 32 is inserted into a piercing tube 39. The piercing tube 39 is located in a placement groove 38. The placement groove 38 is fixedly located inside the installation chamber 2. A sliding valve is slidably arranged inside the sustained-release tube 31. The sliding valve extends out of the sustained-release tube 31 through a guide groove 37 and is connected to the drive mechanism 6. The guide groove 37 is opened through the side of the sustained-release tube 31 near the end of the installation chamber 2. A sustained-release port 36 is provided on the side of the sustained-release tube 31 near the drive mechanism 6.

[0044] In this embodiment, when loading the therapeutic drug, the drug storage tube 32 is first removed, the first plug 34 is pulled out, the drug is injected into the drug storage tube 32, and then the piercing tube 39 is reinserted to reset and seal the first plug 34. The drive mechanism 6 is activated to make the sliding valve reciprocate along the guide groove 37. When the sliding valve moves away from the U-shaped connecting tube 61, a negative pressure is formed in the sustained-release tube 31, causing the drug to be drawn into the sustained-release tube 31 through the U-shaped connecting tube 61 and the first one-way valve 64. When the sliding valve moves towards the U-shaped connecting tube 61, the pressure in the sustained-release tube 31 increases. At this time, the first one-way valve 64 closes, and the drug is slowly released into the installation chamber 2 through the sustained-release port 36 under pressure, thereby completing the timed and quantitative sustained release of the drug.

[0045] In practical use, during the process of drug extraction by the sustained-release tube 31, the piercing tube 39 introduces external gas into the drug reservoir 32 to balance the air pressure and prevent negative pressure from hindering drug flow. An atomizing nozzle is provided at the sustained-release port 36, which can atomize the drug solution into micron-sized particles, improving transdermal absorption efficiency. If the drug reservoir 32 contains a solid drug, the uniformity of air diffusion can be improved when the odor is released.

[0046] It should be noted that by adjusting the reciprocating frequency of the drive mechanism 6, the moving speed and displacement of the sliding valve can be precisely controlled, thereby adjusting the inhaled drug volume and release rate. Furthermore, by combining the physicochemical properties of different drugs with the patient's sleep cycle rhythm, multiple sustained-release modes can be preset to achieve personalized drug delivery. For example, for benzodiazepines, a high-frequency sustained-release mode can be set in the first half of the night to promote sleep, and the frequency can be automatically reduced in the second half of the night to reduce the residual effect the next day; while for melatonin, a phase-shifted release is used, starting peak release two hours before the lowest point of body temperature, precisely matching the endogenous rhythm.

[0047] Optionally, a second one-way valve is provided in the slow-release port 36. The first one-way valve flows from the drug storage tube 32 to the slow-release tube 31, and the second one-way valve flows from the slow-release tube 31 to the installation chamber 2.

[0048] The first one-way valve 64 and the second one-way valve work together to form a bidirectional pressure regulation loop, ensuring that the drug flows into the sustained-release tube 31 and is released into the installation chamber 2 in only one direction, preventing backflow and cross-contamination. Specifically, the first one-way valve 64, in conjunction with the ventilation function of the puncture tube 39, achieves bidirectional isolation between drug absorption and release, preventing outside air from flowing back into the drug storage tube 32 through the puncture tube 39 and causing drug oxidation or contamination. The second one-way valve forms a physical barrier during the drug release stage, preventing ambient gas in the installation chamber 2 from seeping back into the sustained-release tube 31, ensuring the purity and release accuracy of the drug solution. Both valves, in conjunction with the timing control of the drive mechanism 6, ensure that the entire sustained-release process operates synchronously according to a preset rhythm.

[0049] Optionally, a tail plug 33 is provided at the insertion point of the drug storage tube 32 and the piercing tube 39, and a first plug 34 is provided at the connection point of the drug storage tube 32 and the U-shaped connecting tube 61. Both the tail plug 33 and the first plug 34 are made of medical-grade rubber and are sealed at the connection point with the drug storage tube 32. They also have self-sealing properties and high resilience deformation capability, ensuring that the sealing surface fits instantly and without micro-leakage during insertion and removal.

[0050] Optionally, the piercing tube 39 penetrates the installation chamber 2 and connects to the outside, and a filter screen 7 is also provided on the piercing tube 39. The piercing tube 39 allows the drug storage tube 32 to be connected to the external air pressure in real time, while the filter screen 7 effectively blocks the intrusion of environmental dust, microorganisms and condensate, ensuring the cleanliness of the ventilation.

[0051] Optionally, the inner wall of the installation chamber 2 is provided with multiple guide holes 5, and the pillow seat 1 is provided with a pillow surface 8. The guide holes 5 are connected to the corresponding ventilation grooves on the pillow surface 8 to form a through airflow channel, so that the trace amount of volatile gas or water vapor generated in the installation chamber 2 due to drug release can be discharged through the guide holes 5 and the ventilation grooves in coordination, avoiding local accumulation that affects the stability of drug efficacy and patient comfort.

[0052] Optionally, the drive mechanism 6 includes a pull rod 62 connected to the sliding valve, a first connecting rod 63 is provided between the pull rods 62, a second connecting rod 65 is rotatably connected to the first connecting rod 63 via a rotating shaft, the end of the second connecting rod 65 away from the first connecting rod 63 is rotatably mounted on a worm gear 66 via a rotating shaft, the worm gear 66 is rotatably mounted in the mounting chamber 2, the worm gear 66 meshes with a worm 67, the input end of the worm 67 is connected to the output end of a motor 68, and the motor 68 is mounted in the mounting chamber 2.

[0053] It should be noted that the motor 68 drives the worm wheel 66 to rotate precisely through the worm 67. During the rotation, the worm wheel 66 drives the second connecting rod 65 to swing, and then transmits the displacement to the pull rod 62 through the first connecting rod 63. During this process, the pull rod 62 drives the sliding valve to slide back and forth in the slow-release tube 31 according to the preset stroke, thereby controlling the quantitative extraction and release of the medicine liquid in the medicine storage tube 32.

[0054] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.

Claims

1. A sustained-release formula for preventing and treating allergic rhinitis, characterized in that: One dose of the medicine includes 400g-500g of chrysanthemum, 27g-33g of roasted cocklebur, 52g-66g of saposhnikovia root, 52g-66g of centipeda minima, 17g-22g of rose, 53g-66g of wild chrysanthemum, 24g-33g of magnolia flower, 53g-66g of angelica root, 16g-22g of peppermint, 57g-68g of mimosa flower, 54g-62g of honeysuckle, 26g-33g of notopterygium root, 18g-25g of asarum, and 27g-35g of ligusticum root slices. The medicines are mixed in proportion and then pulverized at low temperature. The particle size of the pulverized material is controlled to be 100-200 mesh. After mixing and homogenization, the moisture content of the material is controlled to be below 3%. After low-temperature pulverization and homogenization, the mixture is filled into a pillow.

2. A sustained-release medicated pillow for preventing and treating allergic rhinitis, using the sustained-release formula for preventing and treating allergic rhinitis as described in claim 1, characterized in that: The device includes a pillow base (1), with an installation compartment (2) at the bottom of the pillow base (1). Two sets of slow-release mechanisms (3) are symmetrically installed in the installation compartment (2) along the central axis. A drive mechanism (6) is installed between the two sets of slow-release mechanisms (3) through the installation compartment (2). The drive mechanism (6) is used to drive the two sets of slow-release mechanisms (3). The sustained-release mechanism (3) consists of multiple sets of sustained-release components arranged in parallel. The sustained-release components include a sustained-release tube (31) and a drug storage tube (32). The sustained-release tube (31) and the drug storage tube (32) are connected by a U-shaped connecting pipe (61). A first one-way valve (64) is provided in the U-shaped connecting pipe (61). The drug storage tube (32) is inserted into the piercing tube (39). The piercing tube (39) is set in the placement groove (38). The placement groove (38) is fixedly set in the installation chamber (2). A sliding valve is slidably arranged in the sustained-release tube (31). The sliding valve extends out of the sustained-release tube (31) through the guide groove (37) and is connected to the drive mechanism (6). The guide groove (37) is opened through the side of the sustained-release tube (31) near the end of the installation chamber (2). A sustained-release port (36) is provided on the side of the sustained-release tube (31) near the drive mechanism (6).

3. The sustained-release medicated pillow for preventing and treating allergic rhinitis according to claim 2, characterized in that: The slow-release port (36) is provided with a second one-way valve. The first one-way valve (64) flows from the drug storage tube (32) to the slow-release tube (31), and the second one-way valve flows from the slow-release tube (31) to the installation chamber (2).

4. A sustained-release medicated pillow for preventing and treating allergic rhinitis according to claim 2, characterized in that: A tail plug (33) is provided at the insertion point of the drug storage tube (32) and the piercing tube (39), and a head plug (34) is provided at the connection point of the drug storage tube (32) and the U-shaped connecting tube (61).

5. A sustained-release medicated pillow for preventing and treating allergic rhinitis according to claim 4, characterized in that: Both the tail plug (33) and the head plug (34) are made of rubber and are sealed at the connection with the drug storage tube (32).

6. A sustained-release medicated pillow for preventing and treating allergic rhinitis according to claim 2, characterized in that: The piercing tube (39) passes through the installation chamber (2) and connects to the outside. A filter screen (7) is also provided on the piercing tube (39).

7. A sustained-release medicated pillow for preventing and treating allergic rhinitis according to claim 2, characterized in that: The inner wall of the installation compartment (2) is provided with multiple guide holes (5), and the pillow seat (1) is provided with a pillow surface (8).

8. A sustained-release medicated pillow for preventing and treating allergic rhinitis according to any one of claims 2-7, characterized in that: The drive mechanism (6) includes a pull rod (62) connected to the sliding valve. A first connecting rod (63) is provided between the pull rods (62). A second connecting rod (65) is rotatably provided on the first connecting rod (63) via a rotating shaft. The end of the second connecting rod (65) away from the first connecting rod (63) is rotatably provided on a worm gear (66) via a rotating shaft. The worm gear (66) is rotatably provided in the mounting chamber (2). The worm gear (66) meshes with a worm (67). The input end of the worm (67) is connected to the output end of a motor (68). The motor (68) is provided in the mounting chamber (2).

Images